• Ping An Biomedical shareholders ratified a 40-for-1 share consolidation effective October 23, 2026, at their October 29, 2026, extraordinary meeting.
• Shareholders approved increasing authorized share capital from US$312,500 to US$12.5 million, with adoption of fourth amended articles conditional on that increase.
• The meeting also ratified third amended articles reflecting the consolidation and approved general authorization to implement the resolutions.
• Further share consolidations of 10-for-1, 20-for-1, 50-for-1 or 80-for-1 won approval, subject to specified share-price triggers.
• New amended articles reflecting any further consolidation were approved, with adoption conditional on that consolidation taking effect.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ping An Biomedical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-114431), on October 30, 2026, and is solely responsible for the information contained therein.